leadf
logo-loader
viewPreveCeutical Medical Inc.

PreveCeutical Medical retains Veristat as it prepares for clinical trials on its Sol-Gel coronavirus program

Veristat, a clinical research organization, will help design and develop the coronavirus sol-gel clinical program and write the required protocol

PreveCeutical Medical Inc. -
Preveceutical has been developing the technology since 2017 and spent C$750,000 on research

PreveCeutical Medical Inc (CSE:PREV) (OTCQB:PRVCF) (FSE:18H) told investors it had retained Massachusetts-based Veristat, a global clinical research organization (CRO), to help it prepare for clinical trials of its Sol-Gel coronavirus (COVID-19) program.

As reported in May this year, the health sciences group set out to extend its cannabis sol-gel nasal program to potentially act as a viral prevention to address the pandemic.

READ: PreveCeutical Medical appoints Edward James Henderson as the public officer and director of its (Australia) subsidiary

Vancouver-based Preveceutical has been developing the technology since 2017 and spent C$750,000 on research, not including management and employee overheads.

It works by infusing cannabis extracts into water-based sol-gels, which are delivered to patients using a nasal spray applicator.

"Since the beginning of the pandemic, PreveCeutical has mobilized its scientific understanding to investigate the development of treatments that could potentially reduce the transmission of COVID-19," said Stephen Van Deventer, PreveCeutical's CEO, in a statement on Tuesday.

"We are very pleased with the progress of our COVID-19 Sol-Gel program and are committed to rapidly developing the clinical trial process. To support our efforts, we selected Veristat because of its extensive infectious disease experience and the substantial number of COVID-19 related clinical trials."

Veristat will help design and develop the firm's coronavirus sol-gel clinical program and write the required protocol.

Preveceutical added that it was looking for an expedited pathway such as fast track or COVID-19 treatment acceleration program (CTAP).

It also noted it was not making "any express or implied claims" that its product can eliminate, cure or contain COVID-19 at this time.

Contact the author at giles@proactiveinvestors.com

Quick facts: PreveCeutical Medical Inc.

Price: 0.04 CAD

CSE:PREV
Market: CSE
Market Cap: $19.68 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of PreveCeutical Medical Inc. named herein, including the promotion by the Company of PreveCeutical Medical Inc. in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

PreveCeutical Medical announces completion on analgesic program is near

PreveCeutical Medical (CSE:PREV-OTCQB: PRVCF) CEO Stephen Van Deventer joined Steve Darling from Proactive Vancouver with news the company’s current stage of research for its disulfide linker technology will be completed soon. Van Deventer telling Proactive about the program and what the next...

on 23/7/20

2 min read